Occult blood screening obstacles to effectiveness

Cancer

Volumn 70, Issue 3 S, 1992, Pages 1259-1265

  Ahlquist, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; OCCULT BLOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HUMAN; MASS SCREENING; MIDDLE AGE; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 0026713841     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19920901)70:3+<1259::AID-CNCR2820701511>3.0.CO;2-D     Document Type: Article

References (65)

1. 1989 Survey of physicians' attitudes and practices in early cancer detection
2. Occult blood screening for colorectal carcinoma: a critical review
3. Occult blood screening for colorectal carcinoma: the benefits
4. Occult blood screening for colorectal carcinoma: the risks
5. Occult blood screening for colorectal carcinoma: the yield and the costs
6. Occult blood screening for colorectal cancer
7. Is screening for colorectal cancer worthwhile?
8. Fecal occult blood is an invalid screening marker for colorectal polyps [abstract]
9. Relative sensitivity of the fecal occult blood test and flexible sigmoidoscopy in detecting polyps
10. Screening experience with fecal occult blood testing as a function of age
11. Adenomatous polypi of large intestine: incidence and distribution
12. Adenomatous lesions of the large bowel: an autopsy survey
13. Small adenomas detected during fecal occult blood test screening for colorectal cancer: the impact of serendipity
14. The prevalence of cancer, estimates based on the Connecticut Tumor Registry
15. Randomized controlled trial of faecal occult blood screening for colorectal cancer
16. Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen, Denmark
17. The earlier detection of colorectal cancers: a preliminary report of the results of the Occult Blood Study
18. Screening and rescreening for colorectal cancer: a controlled trial of fecal occult blood testing in 27,700 subjects
19. Screening for colorectal cancer with fecal occult blood test and sigmoidoscopy: preliminary report of the Colon Project of Memorial Sloan‐Kettering Cancer Center and PMI‐Strang Clinic
20. Colorectal cancer detection in the practice setting: impact of fecal blood testing
21. A screening primer: basic principles, criteria, and pitfalls of screening with comments on colorectal carcinoma
22. Compliance with colorectal cancer screening in a high‐risk occupational group
23. Experiences with a nationwide screening program for colorectal cancer in the Federal Republic of West Germany
24. Comparative education approaches to screening for colorectal cancer
25. Randomized trial compliance with screening for colorectal cancer
26. Patient compliance with self‐directed Hemoccult testing
27. A stool collection device: the first step in occult blood testing
28. Occult gastrointestinal bleeding
29. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancer: the University of Minnesota's colon cancer control study
30. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas
31. Fecal blood levels in health and disease: a study using Hemo‐Quant
32. 51chromium‐labeled erythrocytes and with the Hemoccult test
33. Bleeding patterns in colorectal cancer: the effect of aspirin and implications for fecal occult blood testing
34. Measurement of degraded fecal hemoglobin‐heme to estimate gastrointestinal site of occult bleeding: appraisal of its clinical utility
35. HemoQuant, a new quantitative assay for fecal hemoglobin: comparison with Hemoccult
36. Hemoccult stool tests: false‐negative results due to storage of specimens
37. False‐negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C)
38. Sensitivity and reproducibility of chemical tests for fecal occult blood with an emphasis on false‐positive reactions
39. Hemoccult detection of fecal occult blood quantitated by radioassay
40. Immunochemical confirmation of gastrointestinal bleeding
41. Occult blood testing for detection of asymptomatic colon cancer
42. Non‐uniform distribution of occult blood in feces
43. Patterns of occult bleeding in asymptomatic colorectal cancer
44. Accuracy of occult blood tests over a six‐day period
45. Sensitivity of guaiac‐impregnated cards for the detection of colorectal neoplasia
46. Immunochemical detection of fecal occult blood: the fecal smear punch‐disc test: a new non‐invasive screening test for colorectal cancer
47. False‐negative results of Hemoccult test in colorectal screening
48. Hemoccult screening in detecting colorectal neoplasms: sensitivity, specificity, and predictive value: long‐term follow‐up in a large group practice setting
49. Validity of fecal blood measured by HemoQuant in the postoperative surveillance of colorectal neoplasia
50. Sensitivity of fecal Hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening
51. Results of a television‐advertised mass screening program for colorectal cancer using fecal occult blood tests
52. Patient's and doctor's delay in carcinoma of the colon and rectum
53. Mass screening for colorectal cancer
54. Trends in colorectal cancer incidence: United States, 1973‐1986
55. Colorectal cancer: implications of mass screening for public health
56. Factors influencing mortality after curative resection for large bowel cancer in elderly patients
57. Anterior resection for adenocarcinoma of the distal large bowel
58. Resection for colorectal cancer in the very old: are the risks too high?
59. Screening for colorectal cancer
60. Comparing benefits and harms: the balance sheet
61. Screening for colorectal cancer in a high‐risk population: results of a mathematical model